Beam Therapeutics will host an investor webcast on February 24, 2026, to discuss its financial performance for the fourth quarter and full year 2025, along with unveiling a new liver-targeted genetic disease program. The presentation will provide stakeholders with a comprehensive overview of the company's operational achievements and strategic direction across its portfolio.
During the webcast, Beam will outline strategic priorities for its genetic disease and hematology franchises, reflecting its focus on these therapeutic areas. The company has also achieved a significant regulatory milestone, securing FDA alignment on an accelerated approval pathway for BEAM-302, its investigational therapy for Alpha-1 Antitrypsin Deficiency, which could expedite the drug's development timeline.
The briefing represents an opportunity for investors to gain insight into Beam's recent progress, financial position, and long-term strategic initiatives as the company advances its pipeline of precision genetic medicines.